- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | A Phase 2b clinical study for iron.based T1.MRI contrast agent: Advancing towards Phase 3 | ||||||
| Others | Lymphadenopathy | Arthrography using magnetic resonance imaging (MRI) for shouler, hip, elbow, knee, wrist, and ankle | Phase 2 | Inventera Pharmaceuticals Inc. | RS-2023-00282888 | ||
| 2 | Clinical Trial Development of Small Molecule Inhibitor for Progeria Treatment: Progerinin | ||||||
| Small Molecules | Progeria syndromes | Progerin PPI | Phase 2 | PRG S&Tech Inc. | RS-2023-00258708 | ||
| 3 | Development of a HNP-2006 contrast agent with improved safety | ||||||
| Others | MRI contrast agent | Gd-ligand | Phase 2 | Hana Pharm Co., Ltd. | HN21C1298 | ||